CryoLife Announces Release Date for First Quarter Revenues and Earnings And Shareholder Access to Teleconference Call Following Release of First Quarter Results

ATLANTA, April 10 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein-based adhesives, announced today that first quarter revenues and earnings figures would be released on April 17, 2001.

The Company also announced that immediately following the release of financial results, an analysts' teleconference would be held promptly at 11:15 a.m. Eastern Time hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer.

Shareholders interested in listening in on the teleconference may do so by calling (973) 321-1020 a few minutes prior to 11:15 a.m. No identification number is required. Shareholders interested in listening to a replay of the teleconference call may do so by calling (877) 519-4471 (toll free) or (973) 341-3080; the pass code for the replay is 2520407. The replay will be available April 17 through April 20, 2001.

Founded in 1984, CryoLife, Inc., is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is approved as an adjunct for acute thoracic aortic dissections under HDE regulations in the United States and is CE marked in the European Union and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the world's first tissue-engineered heart valve replacement and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE Marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com .

SOURCE CryoLife, Inc.

CONTACT: D. Ashley Lee, Vice President, Chief Financial Officer of CryoLife, Inc., 800-438-8285/